Serial #79230436
LIVE

Serial Number

79230436

Owner

Merxin Ltd

Attorney

Geza C Ziegler Jr

Filing Date

Jan 18, 2018

Add to watchlist:

No watchlists yet
View on USPTO

Serial #79230436 Trademark

Serial Number: 79230436 • Registration: 5759811

Serial #79230436 is a trademark filed by Merxin Ltd on January 18, 2018. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Merxin Ltd (3 trademarks)

King's Lynn Innovation Centre
King's Lynn, Norfolk PE30 5BY , GB

Entity Type: 99

Trademark Details

Filing Date

January 18, 2018

Registration Date

May 28, 2019

Published for Opposition

February 12, 2019

Goods & Services

Vials for scientific purposes being laboratory equipment; Vials for laboratory use; Glass tubes for scientific purposes being laboratory equipment, none of the aforesaid being additive manufacturing devices or 3D devices

Scientific and technological services, namely, research and design in the field of drug delivery via the lungs or via the nasal passageway; Scientific and technological design of new products for others; Advisory services relating to design engineering; Advisory services relating to product testing; Product design and development in the field of drug delivery via the lungs or via the nasal passageway; New product design services, namely, analysis and evaluation of product design; engineering design and consultancy; Professional consultancy relating to medical technology; engineering project management services, not for business purposes; Engineering research; Pharmaceutical research and development services; research and development for the pharmaceutical industry; Research relating to medicines; none of the aforesaid in relation to additive manufacturing services or 3D printing services

[ Pharmaceuticals for treating viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders adapted for delivery into the body via the lungs or via the nasal passageway; Pharmaceutical compositions for treating viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders adapted for delivery into the body via the lungs or via the nasal passageway; Pharmaceutical preparations for treating viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders for delivery into the body via the lungs or via the nasal passageway; Pharmaceutical preparations for inhalers, namely, medical pharmaceutical compositions for treating viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders structured for delivery into the body by nebulizer, aerosol, or dry powder, via the lungs or via the nasal passageway; Dietary supplements; Pharmaceutical products for treating viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for treating viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders ]

Pharmaceutical compounding services; Pharmaceutical compounding consultation services; Pharmaceutical compounding advisory services; Medical services [ ; Veterinary services; Hygienic and beauty care for animals; Hygienic and beauty care for humans ]

[ Surgical, medical, dental and veterinary apparatus and instruments, namely, injection devices for administering drugs sold empty; ] Medical apparatus for facilitating the inhalation of pharmaceutical preparations; [ Medical syringes sold empty for administering pharmaceuticals; ] Medical apparatus for introducing pharmaceutical preparations into the human body; Inhalers for medical use; Medical inhalers; [ Respiratory monitors for medical use; Apparatus for measuring lung function; Spirometers for examining the function of the lungs; Spirometers; Spirometer mouth pieces and tubing; breath gas analyzers for medical diagnostics; ] Replacement cartridges for medical inhalers sold empty; Nebulizer for administering medication in the form of a mist inhaled into the lungs, for treatment of asthma and respiratory diseases

Filing History

PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Jun 14, 2026 INPR
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
Oct 14, 2025 NA75
REGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK.
Oct 14, 2025 C75P
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
Oct 13, 2025 EROP
POST REGISTRATION ACTION MAILED - SEC. 71 & 15
Oct 3, 2025 PR75
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
Oct 3, 2025 EROP
POST REGISTRATION ACTION MAILED - SEC. 71 & 15
Aug 27, 2025 PR75
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Aug 25, 2025 APRE
TEAS SECTION 71 & 15 RECEIVED
May 22, 2025 ES75
TEAS CHANGE OF CORRESPONDENCE RECEIVED
May 16, 2025 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
May 16, 2025 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
May 16, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
May 16, 2025 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
May 16, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
May 16, 2025 COAR
NEW REPRESENTATIVE AT IB RECEIVED
Jun 16, 2024 NREP
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
May 28, 2024 REM3
FINAL DECISION TRANSACTION PROCESSED BY IB
Sep 27, 2019 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Sep 9, 2019 FICS
FINAL DISPOSITION PROCESSED
Sep 9, 2019 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Aug 28, 2019 FICR
CHANGE OF NAME/ADDRESS REC'D FROM IB
Jun 14, 2019 ADCH
REGISTERED-PRINCIPAL REGISTER
May 28, 2019 R.PR
EXAMINERS AMENDMENT MAILED
Apr 24, 2019 CNEA
WITHDRAWN FROM ISSUE - MANAGING ATTORNEY REQUEST
Mar 8, 2019 ISMR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 12, 2019 NPUB
PUBLISHED FOR OPPOSITION
Feb 12, 2019 PUBO
NOTIFICATION PROCESSED BY IB
Feb 8, 2019 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jan 23, 2019 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jan 23, 2019 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 23, 2019 NONP
EXAMINERS AMENDMENT MAILED
Dec 21, 2018 CNEA
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 20, 2018 CNSA
EXAMINER'S AMENDMENT ENTERED
Dec 20, 2018 XAEC
EXAMINERS AMENDMENT -WRITTEN
Dec 20, 2018 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 19, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 19, 2018 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Dec 19, 2018 ERFR
LIMITATION FROM THE IB - REQUEST EXAM REVIEW
Dec 13, 2018 LIME
LIMITATION OF GOODS RECEIVED FROM IB
Nov 2, 2018 LIMG
FINAL REFUSAL MAILED
Aug 1, 2018 CNFR
FINAL REFUSAL WRITTEN
Aug 1, 2018 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 26, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 25, 2018 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 25, 2018 TROA
REFUSAL PROCESSED BY IB
May 20, 2018 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
May 1, 2018 RFCS
REFUSAL PROCESSED BY MPU
May 1, 2018 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Apr 29, 2018 RFCR
NON-FINAL ACTION WRITTEN
Apr 28, 2018 CNRT
ASSIGNED TO EXAMINER
Apr 27, 2018 DOCK
APPLICATION FILING RECEIPT MAILED
Apr 24, 2018 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 20, 2018 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Apr 19, 2018 REPR